ZOLEDRONIC ACID FOR INJECTION CONCENTRATE SOLUTION

Država: Kanada

Jezik: engleski

Izvor: Health Canada

Aktivni sastojci:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE)

Dostupno od:

OMEGA LABORATORIES LIMITED

ATC koda:

M05BA08

INN (International ime):

ZOLEDRONIC ACID

Doziranje:

4MG

Farmaceutski oblik:

SOLUTION

Sastav:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE) 4MG

Administracija rute:

INTRAVENOUS

Jedinice u paketu:

1VIAL*5ML

Tip recepta:

Prescription

Područje terapije:

BONE RESORPTION INHIBITORS

Proizvod sažetak:

Active ingredient group (AIG) number: 0141761002; AHFS:

Status autorizacije:

APPROVED

Datum autorizacije:

2014-02-26

Svojstava lijeka

PRODUCT MONOGRAPH
PR
Z
OLEDRONIC
A
CID
F
OR
I
NJECTION
C
ONCENTRATE
4 mg/5 mL zoledronic acid (as zoledronic acid monohydrate)
Bone Metabolism Regulator
Omega Laboratories Limited
Date of Preparation: February 18, 2014
11 177 Hamon
Montreal, Quebec
H3M 3E4
Control No. 158614, 171670
_ _
_Page 2 of 58 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
.................................................................................................
11
DRUG INTERACTIONS
.................................................................................................
22
DOSAGE AND ADMINISTRATION
.............................................................................
22
OVERDOSAGE
................................................................................................................
27
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 27
STORAGE AND STABILITY
.........................................................................................
32
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 32
PART II: SCIENTIFIC INFORMATION
...............................................................................
34
PHARMACEUTICAL INFORMATION
.........................................................................
34
CLINICAL TRIALS
.........................................................................................................
35
DETAILED PHARMACOLOGY
..................................................